Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination antiplatelet therapy: implications for pharmacists.

Robert L Talbert1, Sarah A Spinier, Jean M Nappi

  • 1College of Pharmacy, University of Texas-Austin, USA. talbert@uthscsa.edu

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)
|December 17, 2002
PubMed
Summary

Suboptimal oral antiplatelet therapy can lead to adverse outcomes in acute coronary syndromes. Recent guideline changes emphasize dual antiplatelet therapy, requiring pharmacist awareness and patient counseling.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advice Provided by a Pharmacy Residency Research Committee.

The Annals of pharmacotherapy·2021
Same author

A Response to: Letter to the Editor Regarding "Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review".

Advances in therapy·2020
Same author

Practical Insight Into Anticoagulation for an Aging Population.

The Senior care pharmacist·2020
Same author

Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.

Advances in therapy·2020
Same author

Key Articles and Guidelines in the Management of Heart Failure: 2018 Update.

Journal of pharmacy practice·2019
Same author

Genome-wide association analysis of common genetic variants of resistant hypertension.

The pharmacogenomics journal·2018

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • National guidelines for acute coronary syndromes (ACS) have been updated.
  • Recent evidence from randomized trials informed these changes.

Observation:

  • Two cases illustrate suboptimal oral antiplatelet therapy.
  • These cases highlight the risks of inadequate antiplatelet treatment.

Findings:

  • The American College of Cardiology and American Heart Association revised guidelines in March 2002.
  • Updated guidelines address antiplatelet and anticoagulant therapy for unstable angina and non-ST-segment elevation myocardial infarction.

Implications:

  • Pharmacists must be aware of updated ACS guidelines.
  • Patient counseling on appropriate antiplatelet drug administration is crucial.

Related Experiment Videos

  • Adherence to revised guidelines can improve patient outcomes in ACS.